GLP-1s and Pregnancy, Fertility and Breastfeeding: What the Labels and Research Actually Say

This is one of the more genuinely two-sided topics in GLP-1 treatment — the same drug class that can restore fertility in some patients can simultaneously undermine the contraceptive method others are relying on, and the breastfeeding guidance depends on a formulation detail that is easy to miss.

Fertility: a real, evidence-backed benefit for some patients

For women with obesity and polycystic ovary syndrome (PCOS), GLP-1 receptor agonists improve fertility through weight reduction and enhanced insulin sensitivity — meta-analyzes cited in a 2026 clinical review found significantly higher spontaneous pregnancy rates in this population¹. This is sometimes called the "GLP-1 baby boom" informally, and it has a real mechanistic basis: PCOS-related infertility is often driven by insulin resistance and excess weight, both of which these drugs address directly. In men, the same review notes metabolic improvements may indirectly enhance reproductive parameters as well¹. If fertility is your goal and PCOS or obesity is part of your history, this is a genuine, documented upside worth discussing with your prescriber — not just a weight-loss side effect.

The same mechanism can undermine oral contraceptives

Here's the part that gets far less attention. The gastrointestinal side effects that slow gastric emptying — the same mechanism behind GLP-1 drug interactions generally — can theoretically compromise the absorption of oral contraceptives¹. Because of this, the same clinical review specifically recommends that non-oral hormonal methods and long-acting reversible contraception may be more reliable options during treatment, particularly for patients experiencing GI side effects¹. If you are on a GLP-1 and specifically trying to avoid pregnancy, an oral contraceptive alone may be less reliable than usual during active GI symptoms — a conversation worth having with your prescriber rather than assuming your existing method is unaffected. Tirzepatide's own FDA label goes further and makes this a specific, recurring instruction rather than a general caution; see GLP-1s and hormonal birth control for the exact labeled requirement and why it applies again at every dose increase.

Pregnancy: discontinue with a real washout window, not immediately

Per Wegovy's FDA prescribing information, semaglutide "may cause fetal harm" based on animal reproduction studies, and the label specifically instructs discontinuing the drug in patients who plan to become pregnant — with a defined washout window of at least 2 months before conception, to account for semaglutide's long half-life². A 2026 clinical review states the equivalent recommendation as an 8-week washout specifically for semaglutide and tirzepatide (versus 2–4 weeks for older, shorter-acting agents)¹ — the same guidance, expressed in weeks rather than months, from an independent source. If a pregnancy occurs while already on treatment, existing human pregnancy-outcome data remains limited: a 2025 study on pregnancy outcomes after semaglutide exposure and a broader 2025 review in the American Journal of Obstetrics and Gynecology both describe the current evidence base as still developing, distinct from the more extensive animal-study data³⁴ — which is exactly why the label calls for stopping proactively rather than waiting to find out.

Breastfeeding: the rule depends on the formulation, not the molecule

This is the detail that surprises almost everyone, including people who've read the injection label carefully. Wegovy's own prescribing information draws a sharp line between its two formulations: for the oral tablet, "breastfeeding is not recommended during treatment with WEGOVY tablets," specifically because the tablet contains SNAC (salcaprozate sodium), an absorption enhancer that is detectable in human milk, with unknown accumulation risk in a breastfeeding infant². For the injection, the label states there are no data on semaglutide or its metabolites in human milk, and — critically — "WEGOVY subcutaneous injection does not contain the SNAC metabolites," so the same blanket "not recommended" language does not appear for the injectable form². In plain terms: it is the tablet's inactive ingredient, not the semaglutide molecule itself, driving the breastfeeding caution — a distinction with real practical consequences if you're choosing between an injection and an oral tablet while breastfeeding is a consideration.

What this means for you

If pregnancy is a goal and PCOS or obesity has been a barrier, ask your prescriber whether a GLP-1 fits your fertility plan — the evidence for benefit in that specific population is real. If avoiding pregnancy is the goal, don't assume your oral contraceptive is unaffected, especially during active GI side effects; ask about a non-oral method. If you're actively trying to conceive, plan for the 2-month (8-week) washout before conception, not a same-day stop. And if breastfeeding, the formulation — tablet versus injection — is the deciding factor the label draws, not the underlying molecule. The labels and clinical reviews behind this are indexed in our research library. Not medical advice — see our medical disclaimer; pregnancy, fertility and breastfeeding decisions should be made with your OB/GYN or prescriber, who knows your full history.